0.9019
price down icon1.89%   -0.0166
 
loading
Schlusskurs vom Vortag:
$0.9185
Offen:
$0.9138
24-Stunden-Volumen:
2.11M
Relative Volume:
0.59
Marktkapitalisierung:
$273.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-63.08M
KGV:
-2.4376
EPS:
-0.37
Netto-Cashflow:
$-72.53M
1W Leistung:
-9.89%
1M Leistung:
-3.97%
6M Leistung:
-51.29%
1J Leistung:
+132.84%
1-Tages-Spanne:
Value
$0.891
$0.9381
1-Wochen-Bereich:
Value
$0.8534
$1.02
52-Wochen-Spanne:
Value
$0.36
$2.105

Ocugen Inc Stock (OCGN) Company Profile

Name
Firmenname
Ocugen Inc
Name
Telefon
484-328-4701
Name
Adresse
11 GREAT VALLEY PARKWAY, MALVERN, PA
Name
Mitarbeiter
84
Name
Twitter
@Ocugen
Name
Nächster Verdiensttermin
2024-11-08
Name
Neueste SEC-Einreichungen
Name
OCGN's Discussions on Twitter

Vergleichen Sie OCGN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
OCGN 0.9018 273.29M 0 -63.08M -72.53M -0.37
VRTX 450.26 115.43B 10.63B -479.80M -1.35B 13.33
REGN 746.54 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 591.88 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 245.32 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.56 24.89B 3.30B -501.07M 1.03B 11.54

Ocugen Inc Stock (OCGN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-15 Eingeleitet Maxim Group Buy
2023-03-01 Hochstufung Chardan Capital Markets Neutral → Buy
2022-08-23 Eingeleitet Mizuho Buy
2022-06-15 Fortgesetzt ROTH Capital Buy
2022-06-02 Eingeleitet Cantor Fitzgerald Overweight
2021-07-26 Eingeleitet Noble Capital Markets Outperform
2021-06-11 Herabstufung ROTH Capital Buy → Neutral
2021-05-07 Herabstufung Cantor Fitzgerald Overweight → Neutral
2021-02-09 Herabstufung Chardan Capital Markets Buy → Neutral
2021-02-04 Hochstufung H.C. Wainwright Neutral → Buy
Alle ansehen

Ocugen Inc Aktie (OCGN) Neueste Nachrichten

pulisher
01:55 AM

Ocugen Announces European Medicines Agency Grants Orphan - GlobeNewswire

01:55 AM
pulisher
Nov 20, 2024

Ocugen reports positive data for OCU400, OCU410 - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch

Nov 20, 2024
pulisher
Nov 20, 2024

Ocugen announces EMA granted orphan medicinal product designation for OCU410ST - TipRanks

Nov 20, 2024
pulisher
Nov 20, 2024

Ocugen Advances Gene Therapy and Financial Strategies in Q3 2024 - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Ocugen's Eye Disease Drug Shows 84% Lesion Reduction, Receives EMA Orphan Status | OCGN Stock News - StockTitan

Nov 20, 2024
pulisher
Nov 19, 2024

Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch

Nov 19, 2024
pulisher
Nov 19, 2024

Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy - Ophthalmology Times

Nov 19, 2024
pulisher
Nov 19, 2024

Ocugen announces preliminary efficacy, safety data from Phase 1/2 OCU410 trial - TipRanks

Nov 19, 2024
pulisher
Nov 19, 2024

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen

Nov 19, 2024
pulisher
Nov 19, 2024

Ocugen Announces Compelling Preliminary Data for OCU410—a - GlobeNewswire

Nov 19, 2024
pulisher
Nov 19, 2024

Ocugen's Eye Treatment Shows 21% Disease Slowdown in Phase 1 Trial Data | OCGN Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 18, 2024

Ocugen Inc. stock falls Monday, underperforms market - MarketWatch

Nov 18, 2024
pulisher
Nov 18, 2024

OCGN Stock: Can New Leadership Save This Biotech Company? - TipRanks

Nov 18, 2024
pulisher
Nov 15, 2024

Ocugen Inc. stock falls Friday, underperforms market - MarketWatch

Nov 15, 2024
pulisher
Nov 15, 2024

Ocugen Appoints Ramesh Ramachandran as Financial Officer - TipRanks

Nov 15, 2024
pulisher
Nov 15, 2024

Dow Jones Transportations Average (DOWT) QuotePress Release - The Globe and Mail

Nov 15, 2024
pulisher
Nov 15, 2024

TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail

Nov 15, 2024
pulisher
Nov 15, 2024

TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail

Nov 15, 2024
pulisher
Nov 15, 2024

Nasdaq Health Care Index (IXHC) QuotePress Release - The Globe and Mail

Nov 15, 2024
pulisher
Nov 15, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Nov 15, 2024
pulisher
Nov 15, 2024

Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail

Nov 15, 2024
pulisher
Nov 15, 2024

Ocugen: Q3 Earnings Snapshot - New Haven Register

Nov 15, 2024
pulisher
Nov 14, 2024

Ocugen, Inc. (OCGN) Quarterly 10-Q Report - Quartzy

Nov 14, 2024
pulisher
Nov 14, 2024

Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch

Nov 14, 2024
pulisher
Nov 14, 2024

Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

SEC Form 10-Q filed by Ocugen Inc. - Quantisnow

Nov 14, 2024
pulisher
Nov 14, 2024

HC Wainwright Has Pessimistic View of Ocugen FY2024 Earnings - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch

Nov 13, 2024
pulisher
Nov 12, 2024

Ocugen to Present Innovations at Nasdaq Clinical Showcase - TipRanks

Nov 12, 2024
pulisher
Nov 11, 2024

Navigating 4 Analyst Ratings For Ocugen - Benzinga

Nov 11, 2024
pulisher
Nov 11, 2024

Ocugen (NASDAQ:OCGN) Given Buy Rating at HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Chardan Capital Reaffirms Buy Rating for Ocugen (NASDAQ:OCGN) - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

Earnings call: Ocugen outlines progress in ophthalmology trials, financials - Investing.com

Nov 09, 2024
pulisher
Nov 09, 2024

Earnings call: Ocugen outlines progress in ophthalmology trials, financials By Investing.com - Investing.com Australia

Nov 09, 2024
pulisher
Nov 09, 2024

Ocugen, Inc. (NASDAQ:OCGN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024
pulisher
Nov 09, 2024

Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

Ocugen: Progress in Gene Therapy and Financial Outlook - TipRanks

Nov 08, 2024
pulisher
Nov 08, 2024

Ocugen (OCGN) Q3 2024 Earnings Call Transcript - The Motley Fool

Nov 08, 2024
pulisher
Nov 08, 2024

OCGN Earnings: Ocugen’s Q3 Results Disappoint - TipRanks

Nov 08, 2024
pulisher
Nov 08, 2024

Ocugen receives $30M credit facility to fund, allocate resources across company - Pennsylvania Business Report

Nov 08, 2024
pulisher
Nov 08, 2024

Ocugen reports Q3 revenue $1.136M, consensus $300,000 - TipRanks

Nov 08, 2024
pulisher
Nov 08, 2024

Ocugen Provides Business Update with Third Quarter 2024 Financial Results - Ocugen

Nov 08, 2024
pulisher
Nov 08, 2024

Ocugen Secures $65M Financing, Extends Runway to 2026 as Gene Therapy Trials Advance | OCGN Stock News - StockTitan

Nov 08, 2024
pulisher
Nov 08, 2024

Ocugen (NASDAQ:OCGN) soars 19% this week, taking one-year gains to 193% - Simply Wall St

Nov 08, 2024
pulisher
Nov 07, 2024

A Preview Of Ocugen's Earnings - Benzinga

Nov 07, 2024
pulisher
Nov 07, 2024

Ocugen Secures $30 Million In Debt Funding - citybiz

Nov 07, 2024
pulisher
Nov 07, 2024

Ocugen Secures $30 Million in Debt Funding - Ocugen

Nov 07, 2024
pulisher
Nov 07, 2024

Ocugen, Inc. Secures $30 Million in Debt Funding - Marketscreener.com

Nov 07, 2024

Finanzdaten der Ocugen Inc-Aktie (OCGN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):